SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (291)10/23/2003 7:02:53 AM
From: nigel bates   of 590
 
CRGN selected another four mAbs during the quarter:
Message 19426996
"...With our first antibody, CR002, expected to enter the clinic next year, this quarter we licensed from Abgenix four fully human monoclonal antibodies that were raised against CuraGen-discovered targets. These fully human monoclonal antibodies have shown high specificity for their drug targets and have promising functional data. It is our hope that the superior characteristics of fully human monoclonal antibodies, combined with targets that are selected based on their involvement in critical mechanisms of disease, will raise the probability that these antibodies show promise for clinical success."...
...These fully human monoclonal antibodies expand CuraGen's preclinical pipeline, and have shown promising data in functional models of cancer in mechanisms believed to be important to the progression of the disease...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News